Loading...
XTAI
3054
Market cap65mUSD
Jun 12, Last price  
23.80TWD
1D
2.59%
1Q
7.21%
Jan 2017
-17.71%
IPO
-89.37%
Name

LIWANLI Innovation Co Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
19.36
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.87%
Rev. gr., 5y
-5.24%
Revenues
99m
+154.98%
1,243,110,0001,019,155,0002,317,240,0002,736,562,0002,443,691,0002,235,930,000834,909,000323,097,000348,213,000185,512,000129,782,000276,879,00047,813,00033,988,00038,887,00099,156,000
Net income
-32m
L
86,816,000117,287,00035,782,000-58,152,000289,775,00015,304,000-103,453,00062,796,00081,910,000891,0002,782,000-13,613,00045,563,000-120,907,0005,103,000-32,074,000
CFO
14m
P
89,430,00078,412,000-157,772,000-104,023,000-89,820,000473,038,00034,044,000112,684,00096,034,000-123,090,000-109,160,000-36,627,000-61,133,00078,479,000-50,343,00014,202,000
Dividend
Jun 28, 20180.4 TWD/sh

Profile

LIWANLI Innovation Co., Ltd. operates in the biomedical science industry. It provides products in the areas of nutrition and healthcare. The company offers Vigoway and powder collection products for male, female, elderly, and children audience. Its products include probiotic enzymes, pro-active nutrients, resveratrol red grape extract, algae DHA soft gels, shea butter with type II collagen soft gels, algae astaxanthin Q10 soft gels, cordyceps militaries powder, tooth guard tablets, bovine and goat's milk bites, bilberry-tablets, DHA and vitamin D3 drops, and other products. The company was formerly known as Carry Technology International Co., Ltd. and changed its name to LIWANLI Innovation Co., Ltd. in 2015. LIWANLI Innovation Co., Ltd. was founded in 1980 and is based in New Taipei City, Taiwan.
URL
http://www.carry.com.tw
IPO date
Jul 22, 2002
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
99,156
154.98%
38,887
14.41%
33,988
-28.91%
Cost of revenue
136,945
77,201
74,135
Unusual Expense (Income)
NOPBT
(37,789)
(38,314)
(40,147)
NOPBT Margin
Operating Taxes
1,166
(382)
655
Tax Rate
NOPAT
(38,955)
(37,932)
(40,802)
Net income
(32,074)
-728.53%
5,103
-104.22%
(120,907)
-365.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,804
2,275
2,288
Long-term debt
361
1,197
2,141
Deferred revenue
Other long-term liabilities
1,170
1,172
2,014
Net debt
(333,217)
(327,833)
(364,635)
Cash flow
Cash from operating activities
14,202
(50,343)
78,479
CAPEX
(8,533)
(112)
(387)
Cash from investing activities
(11,185)
(24)
3,394
Cash from financing activities
(475)
(469)
(1,398)
FCF
(24,449)
(69,877)
(39,489)
Balance
Cash
337,680
356,411
386,295
Long term investments
(2,298)
(25,106)
(17,231)
Excess cash
330,424
329,361
367,365
Stockholders' equity
722,557
835,403
713,203
Invested Capital
425,507
457,960
403,134
ROIC
ROCE
EV
Common stock shares outstanding
79,848
80,653
80,651
Price
24.65
17.38%
21.00
5.26%
19.95
-22.67%
Market cap
1,968,260
16.21%
1,693,713
5.27%
1,608,988
-24.53%
EV
1,635,043
1,395,492
1,279,557
EBITDA
(33,877)
(34,058)
(34,316)
EV/EBITDA
Interest
517
582
313
Interest/NOPBT